Applications of artificial intelligence in drug development using real-world data

• URL: http://arxiv.org/abs/2101.08904v2
• Date: Tue, 2 Feb 2021 17:59:01 GMT
• Title: Applications of artificial intelligence in drug development using real-world data
• Authors: Zhaoyi Chen, Xiong Liu, William Hogan, Elizabeth Shenkman, Jiang Bian
• Abstract summary: The FDA has been actively promoting the use of real-world data (RWD) in drug development. RWD can generate important real-world evidence reflecting the real-world clinical environment where the treatments are used. Machine- and deep-learning (ML/DL) methods have been increasingly used across many stages of the drug development process.
• Score: 3.692950272002333
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: The US Food and Drug Administration (FDA) has been actively promoting the use of real-world data (RWD) in drug development. RWD can generate important real-world evidence reflecting the real-world clinical environment where the treatments are used. Meanwhile, artificial intelligence (AI), especially machine- and deep-learning (ML/DL) methods, have been increasingly used across many stages of the drug development process. Advancements in AI have also provided new strategies to analyze large, multidimensional RWD. Thus, we conducted a rapid review of articles from the past 20 years, to provide an overview of the drug development studies that use both AI and RWD. We found that the most popular applications were adverse event detection, trial recruitment, and drug repurposing. Here, we also discuss current research gaps and future opportunities.

Related papers

• Large Language Models in Drug Discovery and Development: From Disease Mechanisms to Clinical Trials [49.19897427783105]
  The integration of Large Language Models (LLMs) into the drug discovery and development field marks a significant paradigm shift. We investigate how these advanced computational models can uncover target-disease linkage, interpret complex biomedical data, enhance drug molecule design, predict drug efficacy and safety profiles, and facilitate clinical trial processes.
  arXiv  Detail & Related papers  (2024-09-06T02:03:38Z)
• DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning [10.528489471229946]
  We propose a multi-agent framework to enhance the drug repurposing process using state-of-the-art machine learning techniques and knowledge integration. Our framework comprises several specialized agents: an AI Agent trains robust drug-target interaction (DTI) models; a Knowledge Graph Agent utilizes the drug-gene interaction database (DGIdb) to systematically extract DTIs. By integrating outputs from these agents, our system effectively harnesses diverse data sources, including external databases, to propose viable repurposing candidates.
  arXiv  Detail & Related papers  (2024-08-23T21:24:59Z)
• Towards Data-Centric Automatic R&D [17.158255487686997]
  Researchers often seek the potential research directions by reading and then verifying them through experiments. The data-driven black-box deep learning method has demonstrated its effectiveness in a wide range of real-world scenarios. We propose a Real-world Data-centric automatic R&D Benchmark, namely RD2Bench.
  arXiv  Detail & Related papers  (2024-04-17T11:33:21Z)
• Artificial Intelligence for Drug Discovery: Are We There Yet? [0.08306867559432653]
  Drug discovery is adapting to novel technologies such as data science, informatics, and artificial intelligence (AI) to accelerate effective treatment development. This review discusses the use of AI in the three pillars of drug discovery: diseases, targets, and therapeutic modalities, with a focus on small molecule drugs.
  arXiv  Detail & Related papers  (2023-07-13T01:51:26Z)
• ImDrug: A Benchmark for Deep Imbalanced Learning in AI-aided Drug Discovery [79.08833067391093]
  Real-world pharmaceutical datasets often exhibit highly imbalanced distribution. We introduce ImDrug, a benchmark with an open-source Python library which consists of 4 imbalance settings, 11 AI-ready datasets, 54 learning tasks and 16 baseline algorithms tailored for imbalanced learning. It provides an accessible and customizable testbed for problems and solutions spanning a broad spectrum of the drug discovery pipeline.
  arXiv  Detail & Related papers  (2022-09-16T13:35:57Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Multi-View Substructure Learning for Drug-Drug Interaction Prediction [69.34322811160912]
  We propose a novel multi- view drug substructure network for DDI prediction (MSN-DDI) MSN-DDI learns chemical substructures from both the representations of the single drug (intra-view) and the drug pair (inter-view) simultaneously and utilizes the substructures to update the drug representation iteratively. Comprehensive evaluations demonstrate that MSN-DDI has almost solved DDI prediction for existing drugs by achieving a relatively improved accuracy of 19.32% and an over 99% accuracy under the transductive setting.
  arXiv  Detail & Related papers  (2022-03-28T05:44:29Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• DrugOOD: Out-of-Distribution (OOD) Dataset Curator and Benchmark for AI-aided Drug Discovery -- A Focus on Affinity Prediction Problems with Noise Annotations [90.27736364704108]
  We present DrugOOD, a systematic OOD dataset curator and benchmark for AI-aided drug discovery. DrugOOD comes with an open-source Python package that fully automates benchmarking processes. We focus on one of the most crucial problems in AIDD: drug target binding affinity prediction.
  arXiv  Detail & Related papers  (2022-01-24T12:32:48Z)
• Artificial Intelligence in Drug Discovery: Applications and Techniques [33.59138543942538]
  Various AI techniques have been used in a wide range of applications, such as virtual screening and drug design. We first give an overview on drug discovery and discuss related applications, which can be reduced to two major tasks. We then discuss common data resources, molecule representations and benchmark platforms.
  arXiv  Detail & Related papers  (2021-06-09T20:46:44Z)
• When deep learning meets causal inference: a computational framework for drug repurposing from real-world data [12.68717103979673]
  Existing methods for drug repurposing may exist translational issues when applied to human beings. We present an efficient and easily-customized framework for generating and testing multiple candidates for drug repurposing. We demonstrate our framework in a case study of coronary artery disease (CAD) by evaluating the effect of 55 repurposing drug candidates on various disease outcomes.
  arXiv  Detail & Related papers  (2020-07-16T21:30:56Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.